Curaleaf (OTCMKTS:CURLF) Price Target Increased to $6.25 by Analysts at Needham & Company LLC

Curaleaf (OTCMKTS:CURLF) had its target price hoisted by equities researchers at Needham & Company LLC from $5.25 to $6.25 in a report released on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s target price points to a potential upside of 13.64% from the stock’s previous close.

Curaleaf Stock Up 3.8 %

Shares of OTCMKTS CURLF opened at $5.50 on Friday. The company has a market capitalization of $3.56 billion, a P/E ratio of -14.10 and a beta of 1.29. Curaleaf has a 52-week low of $2.36 and a 52-week high of $6.40. The company has a debt-to-equity ratio of 0.87, a quick ratio of 0.41 and a current ratio of 0.85. The company’s 50 day moving average price is $5.06 and its 200-day moving average price is $4.49.

Curaleaf (OTCMKTS:CURLF) last issued its quarterly earnings results on Wednesday, March 6th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.04. The firm had revenue of $345.27 million for the quarter, compared to the consensus estimate of $336.64 million. Curaleaf had a negative net margin of 20.77% and a negative return on equity of 12.93%. Equities analysts forecast that Curaleaf will post -0.18 earnings per share for the current year.

About Curaleaf

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.